Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4771 望隼. Please read: https://finlab.finance/en/setup?stock=4771

No install, open FinLab Studio

4771

望隼 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

strong quality, discounted valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 望隼 to your watchlist to track signal changes on your next visit.
Valuation 60Quality 89Growth 76Momentum 34Chips 40

Is 望隼 a buy? Fundamentals and valuation first

  • Top-tier profitability.Operating margin beats ~92% of the market. Latest quarterly ROE ≈ 5.3%.

  • Valuation is low.PE is in the 23th market percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -0.1% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 33.1%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral -0.06
BearishNeutralBullish

Institutional rotation, concentration steady — neutral

  • Institutional rotation, concentration steady — neutral
  • 元大-莒光 holds 257 lots
  • sellers have 754 lots left, ~114 sessions to clear

Window from 2026-01-17 · Price +6% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 元大-莒光 has accumulated 257 lots since the start (sold 0%), holding.
  • Main distributor 美商高盛 peaked at 294 lots, has sold 28%, 213 left, ~32 sessions to clear at the recent pace.
  • TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +0, retail +0.29pp — little change.
  • Foreign hedge-desk net short Net short -73 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
元大-莒光台灣摩根士丹利兆豐-鹿港兆豐-忠孝富邦-南屯台灣企銀-埔墘
Distributing
美商高盛宏遠證券摩根大通統一-新台中美林凱基-台北
Desks
own scale
元大-信義富邦證券國票-台中兆豐-台中港
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 元大-莒光 +257
    sold 0%
  • 台灣摩根士丹利 +189
    sold 18%· still adding
  • 兆豐-鹿港 +101
    sold 0%
  • 兆豐-忠孝 +82
    sold 15%
  • 富邦-南屯 +82
    sold 1%· still adding
  • 台灣企銀-埔墘 +63
    sold 3%

Distributing

  • 美商高盛 213 left
    sold 28%· ~32 sessions to clear
  • 宏遠證券 137 left
    sold 45%· ~114 sessions to clear
  • 摩根大通 78 left
    sold 52%· ~15 sessions to clear
  • 統一-新台中 25 left
    sold 81%· ~25 sessions to clear
  • 美林 79 left
    sold 33%· ~22 sessions to clear
  • 凱基-台北 63 left
    sold 47%· ~19 sessions to clear

Desks

  • 元大-信義 -271
    unclassified
  • 富邦證券 -139
    unclassified
  • 國票-台中 -131
    unclassified
  • 兆豐-台中港 -128
    unclassified
Still selling 754 lots ~114 sessions to bottom at most
Recent buy/sell force +379 absorbed / -431 sold sellers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 33.13%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

15 historical occurrences (since 2024-03-18)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 71.4%, Sample 14, Median +0.91%, Excess -4.19%, Beat mkt rate 28.6%；60-day: Win 46.2%, Sample 13, Median -0.56%, Excess -20.92%, Beat mkt rate 0%；120-day: Win 30%, Sample 10, Median -2.55%, Excess -36.79%, Beat mkt rate 0%

120 days after: historical avg -11.81%

20-day +1.03%
60-day -4.77%
120-day -11.81%
20-day
60-day
120-day
Win
71.4%
46.2%
30%
Sample
14
13
10
Median
+0.91%
-0.56%
-2.55%
Excess
-4.19%
-20.92%
-36.79%
Beat mkt rate
28.6%
0%
0%

Over 10 occurrences, 120-day forward avg declined 11.81%, lagged the market by 36.79 pts; win rate 30%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

7 times historically; 60-day forward avg -8.24%, win rate 16.7%, beating the market by -25.83 pts on average.

What does 望隼 do? Company profile

生技醫療業；軟式拋棄型隱形眼鏡研發、製造與銷售 上市（台灣證券交易所）

Overview

4771 對應望隼科技股份有限公司，為台灣證券交易所上市普通股，非 ETF、ETN、權證或其他衍生型商品。公司成立於 2012-05-10，總部位於苗栗縣竹南鎮公義里友義路66號3樓，主要從事軟式拋棄型隱形眼鏡之研發、製造及銷售，於 2024-03-18 掛牌上市。董事長為黃修權，總經理為石安。依公開資訊與公司年報，資本額約新台幣 5.85 億元；2025-03-31 從業員工合計 866 人，其中研發人員 102 人、一般人員 764 人。主要股東與經營團隊持股方面，2025-03-25 年報揭露長華電材股份有限公司持有約 13.97%，董事長黃修權約 4.89%，總經理石安約 2.27%；公開股市資料另顯示董監持股約 21% 左右。製造據點包含台灣竹南總部、竹南二廠、中國江蘇河陽廠；公司亦規劃竹南新總部與 GMP 廠房，作為後續擴產與辦公搬遷使用。

Business

望隼的商業模式以 ODM 代工為核心，為全球隱形眼鏡品牌客戶提供從材料開發、光學設計、圖紋設計、打樣、取證、生產到品質管理的完整解決方案；同時也透過子公司與合作品牌進行部分市場通路布局。2024 年營收結構高度集中於隱形眼鏡，年報揭露 2024 年隱形眼鏡營收新台幣 29.93619 億元，占 99.72%，其他收入 838.8 萬元，占 0.28%。產品依使用週期包含日拋、雙週拋、月拋；依功能包含水膠透明片、美瞳彩片、濾藍光鏡片、近視矯正、散光、漸進多焦、運動型鏡片及矽水膠產品。銷售區域以外銷為主，2024 年外銷占 95.60%，內銷占 4.40%；亞洲及其他國家為主要外銷區域。公司年報揭露主要客戶以代號 A、C、D 等匿名呈現，2024 年最大客戶 A 占 19.51%，D 占 15.21%，C 占 10.72%，顯示客戶集中度仍需追蹤但已較 2023 年分散。終端應用以視力矯正、美妝彩片、功能型隱形眼鏡與高透氧矽水膠需求為主；主要市場包括中國、日本、台灣、美國、東南亞，並逐步拓展歐洲。

Outlook 2025–2028

2025 至 2028 年的核心展望可分為四條主線。第一，產品升級：公司 2025 年規劃於日本推出第二代濾藍光與散光產品，中國推出矽水膠與半年度拋美瞳片，美國推出矽水膠產品；年報亦揭露散光、漸進多焦、近視防控及功能性鏡片已進入較成熟且具成本優勢的開發階段。第二，區域擴張：日本市場成熟但功能性產品、散光與多焦需求提升；中國市場受本土品牌與線上通路帶動，美瞳彩片需求強，但價格競爭與景氣波動較大；美國市場進入門檻高，但公司已取得美國運動型鏡片與矽水膠相關證照並開始出貨；東南亞則受人口與所得提升帶動，公司已啟動主要東協國家銷售許可取得。第三，產能擴張：2025 年公司月產能約 5,400 萬至 5,900 萬片，後續報導指出新廠與兩岸擴產將推升 2027 年第一季前月產能至約 8,100 萬片；若訂單延續，2026 至 2027 年營收成長動能主要來自中國、日本、台灣及矽水膠放量。第四，風險與挑戰：中國本土代工及品牌競爭升溫可能壓縮毛利；新廠搬遷與折舊可能短期影響毛利率；美元、人民幣及新台幣匯率波動影響外銷收款；各國醫療器材法規、產品取證時程、PFAS 等材料安全規範趨嚴，均可能影響上市節奏與成本。2027 至 2028 年展望屬研究推估，非公司正式財測，關鍵觀察指標為新廠量產效率、矽水膠在日本與美國放量速度、中國美瞳需求延續性、毛利率能否維持約 40% 水準。

Supply Chain

Upstream
  • HEMA、矽水膠單體及其他高分子化學原料供應商 年報揭露隱形眼鏡上游包含 HEMA、矽水膠相關高分子原料等，但主要供應商名稱以代號或未揭露方式呈現；非可確認之台股掛牌公司。
  • PP杯、PP粒、鋁箔、彩盒等包材供應商 隱形眼鏡包裝上游；年報指出 PP杯、PP料、鋁箔與彩盒等為主要上游投入品，但未揭露具名供應商。
  • 自製光學模仁、塑模與自動化設備整合能力 公司強調光學模仁、塑模自製及 AI 自動化檢測與製程整合為競爭利基；此項為內部垂直整合能力，非外部供應商。
  • 年度進貨占比逾 10% 之供應商甲 2024 年報揭露供應商甲占全年進貨淨額約 10.46%，但名稱匿名，無法確認是否為台股掛牌公司。
Downstream
  • 中國在地一線隱形眼鏡品牌客戶 江蘇視准提供在地化生產、銷售與服務，2019 年起量產出貨並打入中國在地一線品牌供應鏈；具名客戶未公開。
  • 日本隱形眼鏡品牌客戶 台灣廠主要供應日本市場，產品包含濾藍光、散光、矽水膠與彩片等；公司年報及新聞提及日本市場需求強，具名主要客戶未完整公開。
  • 星隼光學股份有限公司 望隼轉投資之台灣醫療器材銷售公司，2024 年底成立，負責台灣市場通路與品牌相關布局；未上市櫃。
  • 美國與東南亞品牌或專業通路客戶 公司已開始供應美國市場並取得部分東南亞銷售許可，終端通路包含眼科、驗光、實體零售與線上通路；具名客戶未公開。

Competitors

  • 精華光學 1565 台股上櫃公司，隱形眼鏡製造與代工同業，與望隼同屬台灣隱形眼鏡產業主要廠商。
  • 晶碩 6491 台股上市公司，隱形眼鏡品牌與製造商，具自有品牌與代工能力，與望隼在彩片、矽水膠及亞洲市場競爭。
  • 視陽 6782 台股上市公司，隱形眼鏡製造與代工同業，市場常與晶碩、望隼並列討論台灣隱形眼鏡三雄。
  • 金可-KY 8406 台股上市公司，具海昌等隱形眼鏡品牌與中國市場通路布局，與望隼在中國及亞洲隱形眼鏡市場存在競合。
  • 嬌生視力保健 Johnson & Johnson Vision 國際四大隱形眼鏡品牌之一，非台股掛牌；在全球專業通路與矽水膠市場具高市占。
  • CooperVision 國際四大隱形眼鏡品牌之一，母公司為美國上市公司 CooperCompanies，非台股掛牌。
  • Alcon 國際四大隱形眼鏡品牌之一，瑞士上市公司，非台股掛牌。
  • Bausch + Lomb 國際四大隱形眼鏡品牌之一，美國上市公司，非台股掛牌。
Sources（12）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.